v3.26.3
SEGMENT REPORTING
 6 Months Ended
Jun. 30, 2026
SEGMENT REPORTING  
SEGMENT REPORTING

12. SEGMENT REPORTING

The Group’s chief operating decision maker, who has been identified as the Board of Directors, evaluates segment performance and allocates resources based on several factors, of which the primary financial measures are operating income and research and development costs.

During the six months ended June 30, 2026 and 2025, the Group operated in sales of Exosome products segment, research and development of CD-19 Armed-T products and GDT cell therapy products segment. The revenue of the Group represented the sales of Exosome products only.

​

12. SEGMENT REPORTING (cont.)

There was no revenue generated and assets allocated for the CD-19 Armed-T products and GDT cell therapy products segments for the six months ended June 30, 2026 and 2025. The Company’s chief operating decision maker evaluates performance based on each reporting segment’s revenue, cost of revenues, operating expenses, operating income (loss), other income (expense), and income (loss) before income taxes. The respective information by segment for the six months ended June 30, 2026 and 2025 were as follows:

For the six months ended June 30, 2026

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

CD-19

​

GDT cell

​

Corporate

​

  ​ ​ ​

​

​

​

Exosome

​

Armed-T

​

therapy

​

and

​

​

​

​

  ​ ​ ​

Products

  ​ ​ ​

Products

  ​ ​ ​

Products

  ​ ​ ​

Unallocated

  ​ ​ ​

Total

Revenue

​

$

1,386,608

​

$

—

​

$

—

​

$

—

​

$

1,386,608

Cost of revenue

​

 

(829,124)

​

 

—

​

 

—

​

 

—

​

 

(829,124)

Gross profit

​

 

557,484

​

 

—

​

 

—

​

 

—

​

 

557,484

Operating expenses

​

 

367,989

​

 

128,536

​

 

1,251,462

​

 

971,674

​

 

2,719,661

Operating profit (loss)

​

 

189,495

​

 

(128,536)

​

 

(1,251,462)

​

 

(971,674)

​

 

(2,162,177)

Other income (expenses), net

​

 

(28)

​

 

—

​

 

—

​

 

—

​

 

(28)

Profit (loss) before income tax

​

 

189,467

​

 

(128,536)

​

 

(1,251,462)

​

 

(971,674)

​

 

(2,162,205)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

As of June 30, 2026

​

 

​

​

 

​

​

 

  ​

​

 

​

​

 

​

Identifiable long-lived assets

​

 

10,746

​

 

—

​

 

—

​

 

149,180

​

 

159,926

Total assets

​

 

695,816

​

 

—

​

 

—

​

 

8,215,322

​

 

8,911,138

​

For the six months ended June 30, 2025:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

CD-19 

​

GDT cell 

​

Corporate 

​

  ​ ​ ​

​

​

​

Exosome

​

Armed-T

​

therapy

​

and

​

​

​

​

  ​ ​ ​

Products

  ​ ​ ​

Products

  ​ ​ ​

Products

  ​ ​ ​

Unallocated

  ​ ​ ​

Total

Revenue

​

$

1,129,238

​

$

—

​

$

—

​

$

—

​

$

1,129,238

Cost of revenue

​

 

(740,172)

​

 

—

​

 

—

​

 

—

​

 

(740,172)

Gross profit

​

 

389,066

​

 

—

​

 

—

​

 

—

​

 

389,066

Operating expenses

​

 

345,929

​

 

357,468

​

 

509,554

​

 

785,857

​

 

1,998,808

Operating income (loss)

​

 

43,137

​

 

(357,468)

​

 

(509,554)

​

 

(785,857)

​

 

(1,609,742)

Other income (expenses), net

​

 

(10,186)

​

 

—

​

 

—

​

 

17,835

​

 

7,649

Profit (loss) before income tax

​

 

32,951

​

 

(357,468)

​

 

(509,554)

​

 

(768,022)

​

 

(1,602,093)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

As of June 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Identifiable long-lived assets

​

​

18,194

​

​

—

​

​

—

​

​

648,831

​

​

667,025

Total assets

​

​

4,202,757

​

​

—

​

​

—

​

​

1,588,821

​

​

5,791,578

​

As of June 30, 2026 and 2025, the Group’s total assets and long-lived assets are under the segments of sales of Exosome Products and Corporate and unallocated. All of the payments incurred for research and development of CD-19 Armed-T products and GDT cell therapy products segments are expensed.